Falchi, L., Nijland, M., Huang, H., Linton, K., Seymour, J., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T., Greil, R., Ubieto, A. J., Gangatharan, S., Benjamini, O., Thieblemont, C., Tucci, A., Elinder-Camburn, A., Illes, A., Novak, J., Pavlovsky, M., McDonald, A., Yoon, D. H., Mishima, Y., Sunkersett, G., Mei, J., Mukherjee, N., Zhu, F., Favaro, E., Morschhauser, F. (2025). primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma. Blood. https://doi.org/10.1182/blood-2025-466